Business Description
BioXcel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US09075P1057
Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.73 | |||||
| Equity-to-Asset | -0.88 | |||||
| Debt-to-Equity | -1.41 | |||||
| Debt-to-EBITDA | -0.73 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -15.17 | |||||
| Beneish M-Score | -1.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -14.5 | |||||
| 3-Year EPS without NRI Growth Rate | -16.6 | |||||
| 3-Year FCF Growth Rate | -20.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 38.27 | |||||
| Future 3-5Y Total Revenue Growth Rate | 152.06 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.51 | |||||
| 9-Day RSI | 64.16 | |||||
| 14-Day RSI | 51.24 | |||||
| 6-1 Month Momentum % | -45.63 | |||||
| 12-1 Month Momentum % | -86.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.57 | |||||
| Quick Ratio | 2.49 | |||||
| Cash Ratio | 2.36 | |||||
| Days Inventory | 565.86 | |||||
| Days Sales Outstanding | 78.9 | |||||
| Days Payable | 3315.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7 | |||||
| Shareholder Yield % | -88.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 24.15 | |||||
| Operating Margin % | -8006.04 | |||||
| Net Margin % | -8715.72 | |||||
| FCF Margin % | -6854.16 | |||||
| ROA % | -132.7 | |||||
| ROIC % | -2934.25 | |||||
| ROC (Joel Greenblatt) % | -8610.8 | |||||
| ROCE % | -168.06 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22.32 | |||||
| EV-to-EBIT | -0.53 | |||||
| EV-to-Forward-EBIT | -0.78 | |||||
| EV-to-EBITDA | -0.53 | |||||
| EV-to-Forward-EBITDA | -0.86 | |||||
| EV-to-Revenue | 41.93 | |||||
| EV-to-Forward-Revenue | 21.04 | |||||
| EV-to-FCF | -0.61 | |||||
| Earnings Yield (Greenblatt) % | -188.68 | |||||
| FCF Yield % | -239.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BTAI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioXcel Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.756 | ||
| EPS (TTM) ($) | -5.18 | ||
| Beta | 0.31 | ||
| Volatility % | 110.14 | ||
| 14-Day RSI | 51.24 | ||
| 14-Day ATR ($) | 0.122112 | ||
| 20-Day SMA ($) | 1.186 | ||
| 12-1 Month Momentum % | -86.7 | ||
| 52-Week Range ($) | 1.035 - 12.2085 | ||
| Shares Outstanding (Mil) | 37.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioXcel Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioXcel Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioXcel Therapeutics Inc Frequently Asked Questions
What is BioXcel Therapeutics Inc(BTAI)'s stock price today?
The current price of BTAI is $1.34. The 52 week high of BTAI is $12.21 and 52 week low is $1.03.
When is next earnings date of BioXcel Therapeutics Inc(BTAI)?
The next earnings date of BioXcel Therapeutics Inc(BTAI) is 2024-08-14 Est..
Does BioXcel Therapeutics Inc(BTAI) pay dividends? If so, how much?
BioXcel Therapeutics Inc(BTAI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers